IBRX
Immunitybio Inc
8.50$
-0.4%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -835.3% | -10,722.5% | -87,711.4% | -108,400.0% | -134,853.2% | -353,741.9% | -28,384.1% | -29,381.0% | -140,628.8% | -58,964.1% | -2,653.3% | -269.2% | |
| 20.0% | 623.7% | 8,197.7% | 12,368.9% | 20,329.8% | 32,655.8% | 2,105.6% | 1,531.0% | 14,392.5% | 2,976.2% | 119.1% | 13.7% | |
| 123.1% | 89,500.4% | 167,845.5% | 82,215.6% | 4,346.8% | 7,955.8% | 361.5% | 6,122.2% | 16,741.3% | 7,904.0% | 233.5% | 32.5% | |
| – | – | – | – | 31,636.2% | -1,562.8% | 2,107.1% | 6,244.6% | 12,084.2% | – | – | – | |
| 9,514.5% | 119.5% | 8,731.8% | 7,173.3% | -1,178.7% | -36,362.8% | 2,704.1% | -1,648.3% | -6,667.1% | 615.4% | -131.7% | -48.0% | |
| 46.6% | 949.6% | 14,909.1% | 77,366.7% | 27,876.6% | 9,969.8% | 275.9% | 3,593.5% | 32,567.5% | 4,917.0% | 46.7% | 3.4% | |
| -46.6% | -74,247.5% | -258,345.5% | 221,226.7% | 121,491.5% | 43,144.2% | -3,274.7% | -9,088.4% | 11,373.8% | -4,898.7% | -83.1% | -132.2% | |
| – | – | – | – | – | 5,293.0% | 734.5% | 35,806.9% | 256.7% | – | – | – | |
| – | -2,033.1% | -36,015.9% | -33,837.8% | -485.1% | -5,816.3% | -83.1% | -435.1% | -256.7% | -553.5% | – | – | |
| – | – | – | – | 76,089.4% | 110,860.5% | 10,528.9% | 36,242.0% | 72,552.1% | 41,579.3% | -0.4% | 2.5% | |
| 10,047.9% | 134,463.1% | -35,363.6% | -77,740.0% | -1,640.4% | 265,765.1% | 24,905.0% | 54,116.0% | 97,338.8% | 89,765.4% | 1,910.0% | 353.3% | |
| 9,166.0% | 49,493.2% | -381,420.5% | 35,086.7% | -15,002.1% | -44,881.4% | -6,758.0% | 15,651.6% | -31,797.9% | 25,855.6% | -826.6% | -48.1% | |
| -881.9% | -11,672.0% | -102,620.5% | -185,766.7% | -162,729.8% | -363,711.6% | -28,660.0% | -32,974.5% | -173,196.3% | -63,881.2% | -2,700.1% | -272.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.